Browsing Tag
PIPE-791
2 posts
Contineum Therapeutics (NASDAQ: CTNM) shares slump after PIPE-307 fails to show efficacy in multiple sclerosis trial
PIPE-307 failed to meet efficacy endpoints in RRMS Phase 2, sending Contineum Therapeutics stock lower. Find out what’s next for PIPE-791 and MDD.
November 21, 2025
PIPE-791 enters clinical phase: Pipeline Therapeutics’ precision approach to neuroinflammation treatment
Pipeline Therapeutics, a clinical-stage biopharmaceutical firm specializing in precision neuroregeneration, has announced the initiation of dosing for the…
August 1, 2023